Table III.

AdVMART1-transduced DC stimulate CTL generationa

Target% Specific Lysis
Donor 1 wk 1Wk 2Wk 3Donor 2 wk 1
M202 (MART-1+A2+)8 ± 0.723 ± 1.020 ± 1.113 ± 0.6
M202 + IFN-γ13 ± 0.830 ± 0.6*23 ± 1.818 ± 0.4*
M202 + anti-class I Ab3 ± 0.3*18 ± 1.2*16 ± 0.5*9 ± 0.5*
M201 (MART-1+/A2)0NTdNT0
M237b , M238c (MART-1/A2+)5 ± 0.3NT05 ± 2.4
HepG2 + AdVMART130 ± 1.622 ± 0.3**6 ± 0.2e37 ± 1.4**
HepG2 + RR516 ± 5.816 ± 1.80 ± 1.2e9 ± 3.1
  • a CTL from CD8-enriched responder cells from each of two donors were tested on a weekly basis for MART-1-specific, MHC class I-restricted cytotoxicity. Data represent lysis at E:T 25:1 and is presented as the mean percentage of specific lysis ± SEM. Significant increases in M202 lysis after IFN-γ treatment or decreases after class I Ab blocking compared with untreated M202 lysis are marked with an asterisk (t test, all differences p < 0.05). Significant increases in lysis of HepG2 cells transduced with AdVMART1 compared with HepG2 cells transduced with AdV RR5 are marked with two asterisks (t test, all differences p < 0.02).

  • b Used at wk 1.

  • c Used at wk 3.

  • d NT, not tested.

  • e Saos-2 transduced with AdVMART1 used at wk 3.